Last updated on May 2018

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy Surgery and/or Radiation Therapy


Brief description of study

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

Detailed Study Description

This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs 30 kg/m2) and stage (Stage II vs III).

The primary objective of this trial is to compare the effect of aspirin versus placebo upon invasive disease free survival (iDFS).

Primary objective To compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients.

Secondary objectives

  1. To compare the effect of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients upon:
  2. Distant disease-free survival
  3. Overall survival
  4. Cardiovascular disease (see Section11.3)
  5. To compare the toxicity of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients.
  6. To assess adherence to aspirin and placebo among early stage node-positive HER2 negative breast cancer patients.
  7. To bank tumor and germline deoxyribonucleic acid (DNA), plasma and urine collected at baseline and sequential plasma and urine collected 2 years later for future measurement of inflammatory markers.
  8. To determine if there are subgroups of participants characterized by lifestyle factors associates with greater inflammation for whom there is greater benefit of aspirin versus placebo upon iDFS.

Patients are followed up to 10 years after study enrollment.

Clinical Study Identifier: NCT02927249

Contact Investigators or Research Sites near you

Start Over

Elaine L. Wade

North Shore Medical Center
Skokie, IL United States
0.52miles
  Connect »

Elaine L. Wade

NorthShore University HealthSystem-Evanston Hospital
Evanston, IL United States
2.87miles
  Connect »

Elaine L. Wade

NorthShore University HealthSystem-Glenbrook Hospital
Glenview, IL United States
3.51miles
  Connect »

Wendy Chen, M.D., MPH

Presence Resurrection Medical Center
Chicago, IL United States
4.28miles
  Connect »

Sigrun Hallmeyer

Advocate Lutheran General Hospital
Park Ridge, IL United States
5.32miles
  Connect »

Stuart A. Krauss

Weiss Memorial Hospital
Chicago, IL United States
5.83miles
  Connect »

Denise A. Levitan

Advocate Illinois Masonic Medical Center
Chicago, IL United States
7.85miles
  Connect »